Drug intelligence / Profile preview

hMN-14 × m734

Development stage: Phase 2
Lead developer: Gilead Sciences
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

hMN-14 × m734 is an investigational, chemically assembled F(ab')2 bispecific antibody construct for pretargeted radioimmunotherapy of carcinoembryonic antigen-expressing cancers. One Fab' arm is derived from the humanized anti-carcinoembryonic antigen antibody hMN-14, while the other is derived from murine anti-DTPA-indium antibody m734. The construct is administered first to localize at carcinoembryonic antigen-positive tumor sites; a separately administered iodine-131-labeled di-DTPA-indium bivalent hapten subsequently binds the m734 arm, concentrating therapeutic radioactivity at the tumor. Clinical studies evaluated this pretargeting system in nonmedullary thyroid carcinoma and metastatic medullary thyroid carcinoma, including a prospective phase II study in medullary thyroid carcinoma. ([jnm.snmjournals.org](https://jnm.snmjournals.org/content/47/2/247))

Other names: hMN-14 + m734hMN-14 x m734hMN14 x m734hMN 14 x m734anti-CEA × anti-DTPA bispecific antibody

Targets

CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)

Beyond the preview

Go deeper on hMN-14 × m734.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hMN-14 × m734.

Explore the full profile